S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Patent
Compositions and methods for treating b-lymphoid malignancies
Andrei Thomas-Tikhonenko,Stephan A. Grupp,John M. Maris,David M. Barrett,Elena Sotillo-Pineiro +4 more
TL;DR: Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm were provided in this paper. But none of the methods were considered in this paper.
Journal ArticleDOI
Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group.
Meaghan Granger,Stephan A. Grupp,Morris Kletzel,Cynthia Kretschmar,Arlene Naranjo,Wendy B. London,Wendy B. London,Lisa Diller,Lisa Diller +8 more
TL;DR: The Pediatric Oncology Group9640 study was designed to establish the feasibility of perform-ing tandem myeloablative procedures in rapid succession supported by peripheral blood stem cells (PBSC) in a cooperative groupsetting and to obtain crude estimates of response and PFS ina tandem HDC/SCR regimen that did not include TBI as mentioned in this paper.
Journal ArticleDOI
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
Jochen Buechner,Stephan A. Grupp,Stephan A. Grupp,Hidefumi Hiramatsu,David T. Teachey,David T. Teachey,Susana Rives,Theodore W. Laetsch,Gregory A. Yanik,Patricia A. Wood,Rakesh Awasthi,Lan Yi,Andrea Chassot-Agostinho,Lamis K. Eldjerou,Barbara De Moerloose +14 more
TL;DR: In this article, a global multicenter experience with CRS-associated coagulopathy after tisagenlecleucel therapy in 137 patients with relapsed or refractory B-cell acute lymphoblastic leukemia from the ELIANA and ENSIGN trials was presented.
Journal Article
Role of mu heavy chain in B cell development. I. Blocked B cell maturation but complete allelic exclusion in the absence of Ig alpha/beta.
TL;DR: Transgenic mice are created in which the B cells express signal-capable and signal-incapable mutant μ chains and differing signaling mechanisms are responsible for the developmental transition and allelic exclusion and thus allows for separate examination of these signaling mechanisms.
Journal ArticleDOI
Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
TL;DR: Early phase trials indicate that tisagenlecleucel significantly improves survival for patients with B-ALL that is refractory or in second or later relapse, which may herald a dramatic shift in the treatment paradigm of this largely fatal disease.